Canadian Procurement Pulse: Your Weekly Contractor Insider

March 2026: Healthcare Focus

Canadian healthcare procurement had a big week, and not entirely for the right reasons.

In Ontario, Supply Ontario is gearing up to replace 12,000 disconnected physician EMRs with a single province wide platform — one of the most significant health IT procurements in Canadian history. In Alberta, a forensic accounting firm reported it could not explain why a renegotiated children's medication contract cost $7 million more than the original, and that $42 million has been paid out for product that was never delivered. In Ottawa, a new task force convened to figure out why Canada keeps buying health technology badly at a national scale.

Three governments, three very different relationships with procurement fundamentals. Here's what it means for contractors.

Alberta's Pain Medication Saga Gets a Second Chapter

Source: CBC News | March 20, 2026

What's Happening

Retired judge Raymond Wyant released an addendum to his October 2025 AHS procurement report. The new findings focus on a 2023 renegotiated contract with medical supplier MHCare — $56 million, up $7 million from the original. Forensic accountants at RSM reviewed it and couldn't find documentation to support the value. As of October 2025, AHS had paid $42 million for zero delivered product.

Of the 1.47 million bottles received under the earlier agreement: 55% were incinerated as hazardous waste, 44% donated internationally, roughly 1% reached hospitals.

The government's position: no evidence of wrongdoing by elected officials, all 18 Wyant recommendations accepted and in implementation.

What It Means For You

Between Us

The $42 million for undelivered product is the headline. The real failure was an order placed before Health Canada approval at 10x the volume officials thought was needed. Everything after that was damage control. Front-end diligence is cheaper.

Publicus Data | FY2021/22 – FY2023/24

AHS is one of the largest health procurement organizations in Canada. Three years, 2,746 contracts, $9.1 billion. Here's what the data actually shows.

The Competition Problem

This is the number that should stop you mid-coffee:

Only 2.9% of AHS spending goes through open competition. The remaining 97% flows through exemptions — most of it legitimately, given the nature of pharmaceutical and clinical service contracting — but the number is striking in the context of the Wyant report findings.

The flip side though: competition can often be a bottleneck. Alberta has seen its population grow dramatically over the past 4 years and has needed to buy health supplies and services in line with that growth. As a result, their approach to procurement enables speed. However, it also enables the type of controversy we are now seeing. Importantly, some governments err to far on the side of competition, which results in slow procurement.

I have respect for and do not envy the balancing act procurement professionals and policymakers need to play in this context.

Spending Is Accelerating Fast

AHS contracted spending nearly doubled in two years. The 2024 jump to $4.0B is significant — that's 48% more than 2023 in a single year.

Where the Money Goes

Healthcare services and pharmaceuticals together account for 67% of all spending. Health IT is a distant third at $413.5M — but it's growing and increasingly competitive.

Pharma: Six Companies, $1.2 Billion

The top six pharmaceutical vendors alone account for over half of AHS's entire pharma budget — and every single one is sole-sourced.

This concentration is largely structural — branded pharmaceuticals are inherently sole-source products. But it explains why the Wyant investigation landed where it did: when nearly all procurement is non-competitive by design, the controls that replace competition matter enormously.

Health IT: Microsoft's House

$413.5M in Health IT across 202 contracts. The vendor breakdown tells a familiar story:

Microsoft captures 36% of AHS's entire Health IT budget. For Canadian health IT vendors, this is the market reality you're working against — and the reason Ontario's provincewide EMR procurement represents a genuine structural opening.

Our Take

The Wyant addendum makes more sense when you see this data. A procurement environment where 97% of contracts are non-competitive isn't broken — it reflects how health systems actually buy drugs and clinical services. But it does mean the governance frameworks that replace open competition have to work. When they don't, there's no market mechanism to catch it.

For vendors: the 2.9% that is competitive is where you have a real shot. Health IT is the most accessible category for new entrants, and AHS's IT spend grew meaningfully over this period. Watch for RFPs carefully — they're rare but real.

Source: CNW Group | March 18, 2026

What's Happening

Health Minister Marjorie Michel announced the new Pharmaceutical and Life Sciences Sector Task Force, co-chaired by CellCarta Biosciences co-founder Martin Leblanc and former Health Canada ADM Michelle Boudreau. Membership will include pharma, biotech, and regulatory representatives. Mandate: identify solutions to improve drug access while growing the domestic sector.

This lands alongside a Council for Canadian Innovators report arguing Canada's fragmented health procurement is both a patient care problem and an economic one — with $2.4 billion in annual efficiency gains sitting on the table if provinces could share procurement outcomes rather than running identical competitive processes dozens of times over.

What It Means For You

Our Take

The fiscal math on healthcare doesn't change with the election result. Vendors who can connect their offering to measurable efficiency gains — not just features — will be better positioned as governments shift toward value-based evaluation. That shift is coming.